Navigation Links
Multi Merci Trial Results Published in Peer Reviewed Journal
Date:3/6/2008

MOUNTAIN VIEW, Calif., March 6 /PRNewswire/ -- Concentric Medical, Inc., the global leader in devices for clot removal in ischemic stroke patients, today announced that the results of its Multi MERCI trial will be published in the April 2008 edition of the medical journal, Stroke. The Multi MERCI trial was the second trial studying safety and efficacy of the Merci Retrieval System(TM), a "corkscrew-type" device that is delivered into the brain and is designed to restore blood flow by engaging, capturing and removing blood clots that cause ischemic stroke. The full, peer reviewed trial results are available now to online subscribers. Stroke is published by the American Heart Association.

In the Multi MERCI trial, patients treated with the newer Merci(R) L5 Retriever had their cerebral blood flow successfully restored 57.3% of the time with the Merci Retrieval System alone. With the addition of adjunctive therapy, physicians successfully restored cerebral blood flow 69.5% of the time. For patients to be successfully revascularized, not only the target vessel, but all treatable downstream vessels needed to achieve TIMI 2 or 3 flow.

In addition, a total of 36% of all patients treated achieved a "good" outcome at 90 days post procedure, a higher rate than reported in any other device trial in large vessel acute ischemic stroke patients. Ninety-day clinical outcomes in stroke trials are generally measured using the modified Rankin Score, a measure of functional independence, with a score of 2 or less considered a good outcome. These outcome data are superior to those reported in recent studies of other devices in which successful revascularization was not as stringently defined.

Multi MERCI was a multi-center, prospective trial including 164 patients treated at 15 hospitals in the United States and Canada. All patients had moderate-to-severe, large vessel ischemic strokes. The trial included patients who were ineligible for or had failed treatment with a clotdissolving drug called t-PA. Patients had treatment initiated up to eight hours after stroke symptom onset, extending the three-hour treatment window for intravenous clot-dissolving drugs.

"We are excited that both clinical outcome and recanalization rates are improved with the next-generation devices tested in the Multi MERCI Trial. This provides further evidence that timely recanalization is a surrogate marker for clinical benefit, especially when one uses the conservative definition of recanalization used in this trial," said Wade Smith, MD, PhD Professor of Neurology at the University of California, San Francisco, and Principal Investigator for the Multi MERCI trial.

About Concentric Medical

Concentric Medical is located in Mountain View, California, and was founded in August 1999. The company manufactures and markets the Merci Retrieval System, which is available in over 250 leading stroke centers around the world. Concentric Medical estimates that over 7,000 patients have been treated with its devices. For more information about Concentric Medical, please visit http://www.concentric-medical.com.

Media Contact:

Andrew Gordon

650-810-1701

agordon@concentric-medical.com


'/>"/>
SOURCE Concentric Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
2. EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study
3. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
4. Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
5. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
6. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
7. Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R)
8. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
9. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... DUBLIN , April 20, 2017 Research ... Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and ... to their offering. ... market for drug delivery technologies will rise from USD 20 Billion ... Global Drug Delivery Technologies - Innovation Driven by Rapidly ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ... 99 percent (n=145/146) of chronic hepatitis C virus ... 5 or 6 and compensated cirrhosis (Child-Pugh A) ... (SVR 12 ) with its investigational, pan-genotypic regimen ... rates were seen following 12 weeks of G/P ...
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
Breaking Medicine Technology:
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... Offering the ... with an oil many times purer and more potent than the market has seen ... of Gstaad, Switzerland, as well as a patented chromatography process for extraction, to produce ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... in hospitals, today announced it has completed a round of funding to accelerate ... and its partners. Black Granite Capital is a growth equity firm focused on ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... the ATA 2017 President’s Awards recipients, comprised of organizations and individuals who ... , The ATA 2017 President’s Awards recognize individuals and organizations on ...
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete Miranda, president and CEO ... Enterprising Women magazine as one of its 2017 Enterprising Women of the Year, ... have demonstrated that they have fast-growth businesses, mentor or actively support other women ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... Miami native ... as a dentist. , “I could have never imagined back in 1991 that this ... said Dr. Gallardo. , Over the last 25 years, Dr. Gallardo has pioneered implant ...
Breaking Medicine News(10 mins):